Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions

被引：22

作者：

Tuttle, Jamison B. ^{[1
]}

Anderson, Marie ^{[1
]}

Bechle, Bruce M. ^{[1
]}

Campbell, Brian M. ^{[1
]}

Chang, Cheng ^{[1
]}

Dounay, Amy B. ^{[1
]}

Evrard, Edelweiss ^{[1
]}

Fonseca, Kari R. ^{[1
]}

Gan, Xinmin ^{[1
]}

Ghosh, Somraj ^{[1
]}

Horner, Weldon ^{[1
]}

James, Larry C. ^{[1
]}

Kim, Ji-Young ^{[1
]}

McAllister, Laura A. ^{[1
]}

Pandit, Jayvardhan ^{[1
]}

Parikh, Vinod D. ^{[1
]}

Rago, Brian J. ^{[1
]}

Salafia, Michelle A. ^{[1
]}

Strick, Christine A. ^{[1
]}

Zawadzke, Laura E. ^{[1
]}

Verhoest, Patrick R. ^{[1
]}

机构：

[1] Pfizer Worldwide Res & Dev, Neurosci Med Chem, Groton, CT 06340 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 01期

关键词：

kynurenine amino transferase; kynurenic acid; aryl hydrocarbon receptor; irreversible inhibition; hydroxamic acid; dose response modeling; in vivo microdialysis; schizophrenia; CATION-PI INTERACTIONS; KYNURENIC ACID; CEREBROSPINAL-FLUID; ELEVATED LEVELS; SCHIZOPHRENIA; RECEPTOR; SITE;

D O I：

10.1021/ml300237v

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4, a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k(inact)/K-i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.

引用

页码：37 / 40

页数：4

共 20 条

[1] Claffey M. M., Bicyclic and Tricyclic Compounds as KAT II inhibitors, Patent No. [WO2010146488, 2010146488]
[2] Copeland RA, 2005, EVALUATION ENZYME IN, V46, P1
[3] Cation-π interactions in protein-protein interfaces
Crowley, PB
Golovin, A
[J]. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2005, 59 (02) : 231 - 239
[4] Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia
Dounay, Arny B.
Anderson, Marie
Bechle, Bruce M.
Campbell, Brian M.
Claffey, Michelle M.
Evdokimov, Artem
Evrard, Edelweiss
Fonseca, Kari R.
Gan, Xinmin
Ghosh, Somraj
Hayward, Matthew M.
Horner, Weldon
Kim, Ji-Young
McAllister, Laura A.
Pandit, Jayvardhan
Paradis, Vanessa
Parikh, Vinod D.
Reese, Matthew R.
Rong, SuoBao
Salafia, Michelle A.
Schuyten, Katherine
Strick, Christine A.
Tuttle, Jamison B.
Valentine, James
Wang, Hong
Zawadzke, Laura E.
Verhoest, Patrick R.
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (03): : 187 - 192
[5] Pyridoxal phosphate enzymes: Mechanistic, structural, and evolutionary considerations
Eliot, AC
Kirsch, JF
[J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2004, 73 : 383 - 415
[6] Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
Erhardt, S
Blennow, K
Nordin, C
Skogh, E
Lindström, LH
Engberg, G
[J]. NEUROSCIENCE LETTERS, 2001, 313 (1-2) : 96 - 98
[7] Pharmacological Manipulation of Kynurenic Acid Potential in the Treatment of Psychiatric Disorders
Erhardt, Sophie
Olsson, Sara K.
Engberg, Goran
[J]. CNS DRUGS, 2009, 23 (02) : 91 - 101
[8] Cation-π interactions in structural biology
Gallivan, JP
Dougherty, DA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) : 9459 - 9464
[9] HAN Q, 2010, J CELL MOL LIFE SCI, V67, P353, DOI DOI 10.1007/S00018-009-0166-4
[10] The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression:: Physiopathological implications
Hilmas, C
Pereira, EFR
Alkondon, M
Rassoulpour, A
Schwarcz, R
Albuquerque, EX
[J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (19) : 7463 - 7473

← 1 2 →